These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30028141)

  • 1. Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1.
    Moya-Garzón MD; Martín Higueras C; Peñalver P; Romera M; Fernandes MX; Franco-Montalbán F; Gómez-Vidal JA; Salido E; Díaz-Gavilán M
    J Med Chem; 2018 Aug; 61(16):7144-7167. PubMed ID: 30028141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I.
    Martin-Higueras C; Luis-Lima S; Salido E
    Mol Ther; 2016 Apr; 24(4):719-25. PubMed ID: 26689264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production.
    Moya-Garzon MD; Rodriguez-Rodriguez B; Martin-Higueras C; Franco-Montalban F; Fernandes MX; Gomez-Vidal JA; Pey AL; Salido E; Diaz-Gavilan M
    Eur J Med Chem; 2022 Jul; 237():114396. PubMed ID: 35500475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay.
    Fargue S; Knight J; Holmes RP; Rumsby G; Danpure CJ
    Biochim Biophys Acta; 2016 Jun; 1862(6):1055-62. PubMed ID: 26854734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of alanine supplementation on oxalate synthesis.
    Wood KD; Freeman BL; Killian ME; Lai WS; Assimos D; Knight J; Fargue S
    Biochim Biophys Acta Mol Basis Dis; 2021 Jan; 1867(1):165981. PubMed ID: 33002578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
    Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J
    J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis of primary hyperoxaluria: clues to innovative treatments.
    Dindo M; Conter C; Oppici E; Ceccarelli V; Marinucci L; Cellini B
    Urolithiasis; 2019 Feb; 47(1):67-78. PubMed ID: 30430197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyproline metabolism in mouse models of primary hyperoxaluria.
    Knight J; Holmes RP; Cramer SD; Takayama T; Salido E
    Am J Physiol Renal Physiol; 2012 Mar; 302(6):F688-93. PubMed ID: 22189945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.
    Li X; Knight J; Fargue S; Buchalski B; Guan Z; Inscho EW; Liebow A; Fitzgerald K; Querbes W; Todd Lowther W; Holmes RP
    Biochim Biophys Acta; 2016 Feb; 1862(2):233-9. PubMed ID: 26655602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
    Lai C; Pursell N; Gierut J; Saxena U; Zhou W; Dills M; Diwanji R; Dutta C; Koser M; Nazef N; Storr R; Kim B; Martin-Higueras C; Salido E; Wang W; Abrams M; Dudek H; Brown BD
    Mol Ther; 2018 Aug; 26(8):1983-1995. PubMed ID: 29914758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Novel, Potent Inhibitors of Hydroxy Acid Oxidase 1 (HAO1) Using DNA-Encoded Chemical Library Screening.
    Lee ECY; McRiner AJ; Georgiadis KE; Liu J; Wang Z; Ferguson AD; Levin B; von Rechenberg M; Hupp CD; Monteiro MI; Keefe AD; Olszewski A; Eyermann CJ; Centrella P; Liu Y; Arora S; Cuozzo JW; Zhang Y; Clark MA; Huguet C; Kohlmann A
    J Med Chem; 2021 May; 64(10):6730-6744. PubMed ID: 33955740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural and Unnatural Compounds Rescue Folding Defects of Human Alanine: Glyoxylate Aminotransferase Leading to Primary Hyperoxaluria Type I.
    Oppici E; Montioli R; Dindo M; Cellini B
    Curr Drug Targets; 2016; 17(13):1482-91. PubMed ID: 26931357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconstruction of human hepatocyte glyoxylate metabolic pathways in stably transformed Chinese-hamster ovary cells.
    Behnam JT; Williams EL; Brink S; Rumsby G; Danpure CJ
    Biochem J; 2006 Mar; 394(Pt 2):409-16. PubMed ID: 16309382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
    Chetyrkin SV; Kim D; Belmont JM; Scheinman JI; Hudson BG; Voziyan PA
    Kidney Int; 2005 Jan; 67(1):53-60. PubMed ID: 15610227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactate dehydrogenase A inhibitors with a 2,8-dioxabicyclo[3.3.1]nonane scaffold: A contribution to molecular therapies for primary hyperoxalurias.
    Alejo-Armijo A; Cuadrado C; Altarejos J; Fernandes MX; Salido E; Diaz-Gavilan M; Salido S
    Bioorg Chem; 2022 Dec; 129():106127. PubMed ID: 36113265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.
    Dutta C; Avitahl-Curtis N; Pursell N; Larsson Cohen M; Holmes B; Diwanji R; Zhou W; Apponi L; Koser M; Ying B; Chen D; Shui X; Saxena U; Cyr WA; Shah A; Nazef N; Wang W; Abrams M; Dudek H; Salido E; Brown BD; Lai C
    Mol Ther; 2016 Apr; 24(4):770-8. PubMed ID: 26758691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lumasiran: First Approval.
    Scott LJ; Keam SJ
    Drugs; 2021 Feb; 81(2):277-282. PubMed ID: 33405070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.
    Zabaleta N; Barberia M; Martin-Higueras C; Zapata-Linares N; Betancor I; Rodriguez S; Martinez-Turrillas R; Torella L; Vales A; Olagüe C; Vilas-Zornoza A; Castro-Labrador L; Lara-Astiaso D; Prosper F; Salido E; Gonzalez-Aseguinolaza G; Rodriguez-Madoz JR
    Nat Commun; 2018 Dec; 9(1):5454. PubMed ID: 30575740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous Oxalate Production in Primary Hyperoxaluria Type 1 Patients.
    Garrelfs SF; van Harskamp D; Peters-Sengers H; van den Akker CHP; Wanders RJA; Wijburg FA; van Goudoever JB; Groothoff JW; Schierbeek H; Oosterveld MJS
    J Am Soc Nephrol; 2021 Dec; 32(12):3175-3186. PubMed ID: 34686543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
    Scheinman JI; Voziyan PA; Belmont JM; Chetyrkin SV; Kim D; Hudson BG
    Urol Res; 2005 Nov; 33(5):368-71. PubMed ID: 16292584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.